Augmenix Snags $6.1M
Luke Timmerman10/19/09
Waltham, MA-based Augmenix, the maker of implantable material to minimize the side effects of radiation therapy, said today it has closed a Series B round of financing worth $6.1 million. Ascension Health Ventures led the round, and was joined by Versant Ventures, Pinnacle Ventures, Catalyst Health Ventures, and several private investors, the company said. The company plans to use the money for clinical and commercial development of its SpaceOAR System in the U.S. and Europe, and to develop other products in its pipeline.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
